|
Medical News FDA Fast-Tracks Salix's Diarrhea Drug ReviewFebruary 13, 2012 The US Food and Drug Administration has granted priority review designation to crofelemer, an experimental treatment for HIV-associated diarrhea, the manufacturer Salix Pharmaceuticals Ltd. reported. Priority review status means the agency aims to complete its analysis of the application within six months, rather than the customary 10 months; FDA has set an action date of June 5 for the application. Salix -- based in Raleigh, N.C. -- holds North American and European rights to the drug; it has a supply agreement with India's Glenmark Pharmaceuticals Ltd. Reuters 02.07.2012 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|